Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility imaging study of 89Zr-labeled durvalumab in stage IV non-small-cell lung cancer
2015-005765-23Phase 4Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2017
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Amsterdam University Medical Center. Primary endpoint: 89Zr-durvalumab tumor uptake detection. Started Jul 2017; status: active.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2015-005765-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005765-23.